Last Week in Biomedicine — every Tuesday. Ten of the week's most significant biopharma stories: Phase 2 and Phase 3 trial readouts, breakthrough therapies, FDA updates, and the data driving drug development. For biotech investors, clinicians, researchers, and anyone following the next generation of medicine.
About
TrialBreaks is an independent editorial brief covering clinical trial results, breakthrough therapies, and the broader pipeline of drug development. We surface positive Phase 2 and Phase 3 readouts as they happen, with plain-language summaries built for biotech investors, clinicians, researchers, and anyone following biopharma.Last Week in Biomedicine, our weekly podcast, drops every Tuesday — ten of the previous week's most significant biopharma stories distilled into a single accessible briefing. Individual posts run throughout the week on social media for as-they-happen trial readouts.The weekly podcast is produced using Google's NotebookLM, which generates an AI-narrated audio briefing from a curated research package. We curate and review the source material; the AI handles narration. We disclose this up front because audiences deserve to know how the content they're consuming gets made.Every drug, every effect size, every endpoint we cite traces back to a primary source — a peer-reviewed paper, a sponsor press release, a regulatory filing, or a conference presentation. Sponsors do not influence editorial coverage. If we get something wrong, we correct it on the next episode.
Legal
This page covers our medical disclaimer and privacy policy in plain language.Medical disclaimer. TrialBreaks publishes plain-language summaries of publicly reported clinical trial results and biomedical research. The content is for general educational purposes only. It is not medical advice, diagnosis, or treatment. A positive Phase 2 or Phase 3 trial result means a single trial met its endpoint — not that a drug is safe, available, or right for any individual. If you're considering changes to your treatment, talk to a qualified clinician who knows your medical history. In a medical emergency, contact emergency services immediately.No medical or investment advice. The AI-generated narration on our podcast is not a licensed medical professional, and coverage of a trial, drug, or developer does not constitute endorsement. Some listeners follow clinical trial news for investment purposes — TrialBreaks is not investment advice. Consult a licensed financial advisor before making investment decisions.Privacy. We collect the minimum information needed to operate the show — server logs (IP, browser, timestamp, retained 90 days), and your email address if you contact us or sign up for a newsletter. We do not sell your information. We do not use it for advertising. Podcast listening data is governed by each platform's own policies (Spotify, Apple Podcasts, Amazon Music, etc.) — not ours.Third-party services. To operate TrialBreaks we use Cloudflare (hosting + DNS), Carrd (this website), Spotify for Creators (podcast hosting), Anthropic (AI-assisted research), and Google NotebookLM (podcast audio generation). Each operates under its own privacy policy.Your rights. Depending on where you live, you may have the right to access, correct, or delete the personal information we hold about you. Email [email protected] to exercise these rights.Corrections. If you spot a factual error in any episode or post, email [email protected]. We address corrections on the next episode and on this site.Last updated: May 13, 2026.
Contact
We read every email. Reasonable response time is 2–3 business days.General inquiries: [email protected]
Corrections: [email protected]
Press and interviews: [email protected]
Sponsorship and partnerships: [email protected]
Privacy and legal: [email protected]Find us on the platforms: Spotify, Apple Podcasts, Amazon Music, Pocket Casts, Overcast, Castbox.Please do not send unsolicited drug recommendations, investment advice requests, or personal medical questions. For medical questions, please consult a licensed clinician (see Legal).